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ABSTRACT
Objectives: The aim of the study was to evaluate obstetric care of pregnant women with regard to prevention of congenital 
toxoplasmosis. Additionally, we attempted to determine the frequency of markers for past infection with Toxoplasma gondii 
in order to characterize the current significance of preventive measures in the Polish population. 
Material and methods: The analysis of the medical records — pregnancy charts of women who presented for delivery — was 
performed. Patient age, place of residence, and toxoplasmosis test (or lack of it) were evaluated. Also, further diagnostic 
management, depending on the serologic result, was investigated. 
Results: Out of 670 pregnant women, 628 (93.73%) underwent at least one toxoplasmosis diagnostic test. Out of those, 
502 (73%) had a negative result (IgG –, IgM –), and 2 (0.32%) had a positive result (IgG +, IgM +), while history of infection 
with Toxoplasma gondii was confirmed (IgG +, IgM –) in 124 (19.75%) cases. Repeat testing was required in 183 (29.14%) 
out of the 628 women. 
Conclusions: A high rate of women in whom IgG antibodies were not detected in the first test and a low rate of women 
who required repeat testing later in pregnancy are noteworthy. Regardless of the healthcare policy, parents should receive 
reliable information about the nature of the disease and possibilities of prevention, while medical professionals ought to 
have easy access to research data about the epidemiologic status and recommendations. 
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INTRODUCTION
Toxoplasmosis remains to be one of the most com-
mon parasitic zoonoses and constitutes a serious threat to 
neonates born to mothers with an active infection during 
pregnancy. The global literature reports significant diversity 
in terms of women who exhibit anti-Toxoplasma antibodies, 
which confirms past infection. According to meta-analyses 
which investigated studies in women of the reproductive 
age between 1990 and 2000, a high (over 50%) rate of sero-
positive results was found in Central Europe, Latin America, 
and eastern Africa. Significantly lower rates have been re-
ported for inhabitants of eastern Asia, Scandinavian coun-
tries, and the US [1, 2]. The results are often conflicting, 
even within the investigated countries. Furthermore, various 
authors have emphasized the role of patient age, place of 
residence, and climate, as well as contact with cats, agricul-
ture jobs, dietary habits and hygiene [3].
Human hosts become infected with Toxoplasma gondii at 
various stages of its development: oocysts excreted by a cat 
through food, water, dirty hands, cysts from contaminated 
meat, trophozoites which overcome the placental barrier to 
the fetus or, albeit rarely, through blood and blood product 
transfusions or transplant [4]. Acquired toxoplasmosis is typi-
cally oligosymptomatic, with lymphadenopathy of the neck 
glands, flu-like symptoms, fever, muscle pain, headache, and 
fatigue. On rare occasions, the disease leads to a general infec-
tion, affecting the liver, lungs, heart muscle, skeletal muscles, 
and brain. Often, seroconversion is the only proof of past 
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infection due to indistinct symptoms [5]. Primary infection 
in a pregnant woman presents a particularly challenging is-
sue for obstetricians and neonatologists due to the potential 
risk of transplacental transmission and fetal infection. The 
risk for transmission increases with gestational age while 
symptom intensity increases with duration of pregnancy. In 
the first trimester, the infection may result in miscarriage or 
intrauterine fetal death. In the other trimesters, it may lead 
to non-immune hydrops fetalis, hydrocephaly, microcephaly, 
intracranial calcification, or retinitis. Damage to the fetus 
may result in blindness, disturbed psychomotor and mental 
development, preterm labor, intrauterine growth restriction, 
and neonatal demise [6]. Long-terms studies on the effects 
of past infection on disturbed brain function and behavior 
have also been published [7].
As far as prevention of the congenital infection is con-
cerned, early diagnosis of seroconversion in a seronegative 
pregnant woman is vital as immediate and effective therapy 
prevents the protozoan from transplacental transmission. 
Toxoplasma-specific IgG and IgM antibodies are used to 
determine the serologic status of a pregnant woman [8, 9]. 
Early diagnosis and immediate treatment of the mother play 
the key role in toxoplasmosis prevention. Attitudes to pre-
vention of toxoplasmosis vary around the world. In Poland, 
the first toxoplasmosis test is recommended at 10 weeks of 
gestation. Repeat testing is recommended for seronegative 
women between 21 and 26 weeks of gestation. Preventive 
measure include avoidance of raw, rare and under-cooked 
meat and its products, thorough hand washing and clean-
ing of the utensils after contact with meat, washing fruit 
and vegetables, keeping food away from cockroaches and 
flies, drinking boiled water and milk, thorough washing of 
hands after contact with soil or use of protective gloves, and 
avoidance of objects which might have been in contact with 
cat feces. Pregnant women who dwell in low-risk countries 
should avoid trips to high-risk countries [10].
Objectives
The aim of the study was to evaluate obstetric care of 
pregnant women with regard to prevention of congenital 
toxoplasmosis. Additionally, we attempted to determine 
the frequency of markers for past infection with Toxoplasma 
gondii in order to characterize the current significance of 
preventive measures in the Polish population.
MATERIAL AND METHODS
The study was conducted between December 1, 
2016 and April 30, 2017 in four public hospitals (1 tertiary 
and 3 secondary referral centers) of the Wielkopolskie Re-
gion. Local Ethics Committee approved of the study. The 
analysis of the medical records — pregnancy charts of 
women admitted for delivery — was performed. Patient 
age, place of residence, and toxoplasmosis test (or lack of 
it) were evaluated. Also, further diagnostic management, 
depending on the serologic result, was investigated. Out 
of the 800 pregnancy charts, 670 carts with comprehensive 
and complete data were included in the study. Statistical 
analysis was performed with JMP PRO12 software, using 
Chi square test. The α value of = 0.05 was considered as 
statistically significant. 
Study population
Women aged 18–44 years were admitted for delivery dur-
ing data collection, with subjects aged 21–30 years (55.07%) 
as the largest group, followed by 31–40 years (276 women; 
41.19%), < 20 years (16 women; 2.39%) and > 40 years (9 wom-
en; 1.34%). An overwhelming majority of the parturients 
(517 women, 77.4%) were city dwellers, and the remain-
ing subjects were inhabitants of rural areas (151 women, 
22.6%). The charts were collected between 32 and 41 weeks 
of gestation. Out of the women who presented for deliv-
ery, 150 (22.39) were admitted at 36 weeks of gestation and 
520 (77.61%) between 37 and 42 weeks of gestation. 
RESULTS
Out of 670 pregnant women, 628 (93.73%) underwent 
at least one toxoplasmosis diagnostic test, and 42 (6.27%) 
did not undergo the test. Out of the 628 (100%) women, 
502 (73%) had a negative result (IgG –, IgM –), and 2 (0.32%) 
had a positive result (IgG +, IgM +), while history of infec-
tion with Toxoplasma gondii was confirmed (IgG +, IgM –) 
in 124 (19.75%) cases. Pregnancy charts of women who 
seroconverted during pregnancy were excluded from the 
analysis. Repeat testing was required in 183 (29.14%) out of 
the 628 women who underwent the test (Tab. 1).
No statistically significant differences were found in 
serologic results between different age groups, or between 
city dwellers and inhabitants of rural areas. 
DISCUSSION
The analysis of pregnancy charts revealed that 
628 (93.73%) women underwent toxoplasmosis testing 
at least once during pregnancy, but repeat testing was 
Table 1. Repeat serologic testing, depending on the primary result
Primary result Number (%)
Repeat testing 
number (%)
No repeat testing 
number (%)
Negative result
(IgG –, IgM –) 502 (100%) 170 (33.86%) 332 (66.14%)
Past infection
(IgG +, IgM –) 124 (100%) 11 (8.87%) 113 (91.13%)
Positive result 
(IgG +, IgM +) 2 (100%) 2 (100%) 0 (0%)
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performed in only 183 (29.14%) subjects. The number of 
seronegative women, i.e. at risk for primary infection dur-
ing pregnancy, is important in the prevention of congenital 
toxoplasmosis. In their case, repeat testing is recommended 
between 21 and 26 weeks of gestation. The authors of a study 
from 2007, published in Polish Gynecology, evaluated only 
the fact that the test was or was not performed, without the 
analysis of repeat testing in seronegative women. They also 
demonstrated that a single toxoplasmosis test was conducted 
in over 90% of the parturients, and observed a high rate of 
seronegative IgG women (80% of the respondents) [10]. 
In our study, as many as 520 (73%) women had nega-
tive results for both, IgG and IgM, but repeat testing was 
performed in only 170 (33.89%) subjects. Studies conducted 
between 1997 and 2003 are scarce, but the reports from 
Łodź and Giżycko confirmed the number of seropositive 
women to be significantly higher (41.3% and 44.29%, re-
spectively) [11, 12]. A study on toxoplasmosis from the 
Wielkopolska Region, conducted between 1990 and 2000, 
also reported a significant decrease in the number of se-
ropositive pregnant women, from 58.9 to 43.7% [13]. The 
Polish studies are historical in nature but more up-to-date 
findings have been published for other countries, where 
screening for toxoplasmosis in pregnancy is more common 
and has been carried out for years. In Austria, a significant 
drop was observed between 1995 and 2012, from 43.3 to 
31.5%, while the age-standardized seropositive rate in the 
US also dropped from 14.1 to 6.7% among native inhabitants 
between 1988 and 2010 [14].
Nevertheless, the decreasing rates of seropositive 
women are associated with elevated risk for primary infec-
tion with Toxoplasma gondii during pregnancy. Between 
2008 and 2016, the National Institute of Hygiene reported 
notably increased morbidity and incidence rates of con-
genital Toxoplasmosis (8; 1.93/100 000 — 20; 5.42/100 000, 
respectively). The lowest (3; 0.72/100 000), and the highest 
(21; 5.60/100 000) numbers were observed in 2009 and 
2014, respectively [15–19]. Several European countries have 
launched free of charge screening programs for Toxoplas-
mosis in pregnant women. Austria, France, and Slovenia 
recommend the first testing to take place in the first trimes-
ter of pregnancy, and repeat testing to be performed in the 
second and third trimesters, with the exception of France, 
where the test is repeated every month until the end of 
pregnancy [20, 21]. Countries where such preventive free 
of charge programs for pregnant women are not available, 
have created algorithms which include a combination of 
serologic, biological and molecular diagnostic methods, 
allowing for a quick diagnosis and timely treatment of the 
infected mothers and/or the newborns [22]. Some of the 
abovementioned studies have demonstrated a lack of cor-
relation between the presence of antibodies to Toxoplasma 
gondii and age or place of residence, which is consistent 
with our findings, indicating the need to offer the same care 
to all women, regardless of their age and place of residence.
Lack of continuity of serologic testing during the 
next trimesters of pregnancy in a significant number of 
seronegative women is an alarming finding in our study. 
We also investigated why repeat testing was performed in 
11 (8.87%) women who tested positive for IgG but negative 
for IgM, which is indicative of a past infection. A detailed 
analysis revealed that in 8 of the women the repeat test 
was ordered due to high concentrations of IgG antibodies 
(10.8–606 IU/mL) in the first test, which was the correct 
course of action as significant increase of IgG antibodies 
in the maternal serum may be suggestive of an activation 
of the infection. However, in the remaining 11 women the 
IgG values were not high and IgM antibodies were not ob-
served, so we were not able to find a rational reason why 
repeat testing was ordered. Out of the seronegative women, 
4 underwent only IgM testing (negative IgM test result), and 
out of the women with history of past infection, 1 under-
went only IgG testing (positive IgG test result). According 
to guidelines, the IgM test alone is of little value due to the 
fact that it does not determine past infections, whereas 
the IgG test alone allows to refrain from further testing 
procedures. Importantly, the guidelines should be followed, 
especially the requirement to perform the first test early 
in pregnancy and repeat testing in the next trimesters. In 
Poland, the test is not free of charge, which might be the 
reason why < 100% of the women take the test in the first 
place, and why only 33.89% seronegative women repeat 
the test. However, others reasons, apart from the financial 
aspect, should also be considered, as in France and Aus-
tria — countries with considerable experience with free of 
charge screening — repeat testing is also often omitted. 
Attempts have been made to introduce a means of control 
for the testing process by national health institutions [23].
In our study, we found no cases of seroconversion — pa-
tients with a confirmed infection during pregnancy receive 
further care and treatment, and after delivery are most prob-
ably immediately transferred to the pathology of pregnancy 
ward. The 2 women (aged 24 and 30, respectively, and both 
were city dwellers) who tested positive underwent further 
diagnostic testing and received parasitological consultation, 
which excluded the threat for the current pregnancy and 
found no basis for antiparasite treatment.
Primary infection with Toxoplasma gondii during preg-
nancy, if left untreated, leads to multi-organ complications, 
including fetal or neonatal death. Questions about the ef-
fectiveness of therapy for placental transmission and the 
possible damage to the fetus, in other words the rationale 
behind preventive treatment, have been raised. Multi-center 
studies from several European countries have found no cor-
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relation between the treatment and the transmission. How-
ever, children born to mothers who received treatment were 
significantly less affected. Also, timely intervention proved 
to be important [24], although another meta-analysis (2007), 
did not confirm the link between early (up to 3 weeks from 
the diagnosis of seroconversion) and late (8 or more weeks) 
intervention in terms of maternal-fetal transmission and 
clinical symptoms of the fetal infection [25]. Regardless, the 
literature offers numerous reports on severe complications 
in fetuses of mothers who received the therapy too late, 
so further studies on benefits of treating Toxoplasmosis in 
pregnancy are necessary [26].
It is important to be aware of the differences between 
Poland and other countries as far as guidelines and testing 
procedures for Toxoplasmosis prevention are concerned. 
Data from France and the US, where both, the epidemio-
logic situation and various preventive strategies against 
congenital Toxoplasmosis are different, have been com-
pared. The number of seronegative pregnant women is 
significantly higher in France as compared to the US (37% 
and 9.1%, respectively), the incidence among seronega-
tive women is also higher (2.1/100 000 and 0.2/100 000, 
respectively), as well as the incidence of congenital Toxo-
plasmosis (2.9/100 000 and 0.5/100 000, respectively). Due 
to the abovementioned epidemiologic situation, France 
introduced a free of charge screening program over 30 years 
ago. In the US, lack of a large-scale screening program does 
not allow to detect new cases of infection with Toxoplasma 
gondii among pregnant women. As a result, treatment is 
not introduced and a significantly higher rate of severely 
affected children has been reported as compared to France 
(77% and 3%, respectively) [27]. 
Regardless of the abovementioned studies, detailed 
analysis about the benefits of introducing a screening pro-
gram have been performed. Taking into account all epide-
miologic differences associated with Toxoplasmosis in the 
US, screening of pregnant women, even despite testing and 
therapy costs, has proven to be cost-saving [28]. 
The possibilities of screening continue to change, which 
is associated with the epidemiologic situation as well as 
quality and cost of testing. New tests, which require a small 
amount of blood and allow for a faster and cheaper testing 
of both, the mother and the child, continue to appear on 
the market [29, 30].
Also, health education has been given more attention 
as far as Toxoplasmosis prevention is concerned. However, 
healthcare professionals seem to be focused predominant-
ly on adequate performance and fail to devote sufficient 
amount of time to educating their patients. It is necessary 
to integrate clinical medicine with public and environmental 
health, which might result in spectacularly improved out-
comes [31]. Apart from the abovementioned educational 
measures targeting people at direct risk for infection, the 
French studies have emphasized the need to reach to live-
stock producers and meat processing factories [32]. In our 
study, we were not able to evaluate the educational ini-
tiatives among pregnant women, but the studies from the 
Institute of Mother and Child in Łodź and County Hospital 
in Pabianice on the state of knowledge about Toxoplasmo-
sis among ob-gyns, midwives, and pregnant women have 
revealed insufficient knowledge about the matter among 
the future mothers [33]. At present, health education in 
Poland conducted among pregnant patients by doctors 
and midwives from 21 weeks of gestations ought to include 
Toxoplasmosis control and prevention.
In conclusion, the high rate of women with undetected 
IgG antibodies on first testing and the low rate of women 
who underwent repeat testing are important findings of our 
study. Regardless of the healthcare policy, parents should 
receive reliable information about the nature of the disease 
and possibilities of prevention, while medical profession-
als ought to have easy access to research data about the 
epidemiologic status and recommendations. Furthermore, 
it is important to continue studies of screening profitability 
and diagnostic testing, as they will allow for simple and 
inexpensive diagnostic procedures for both, the mother 
and the child. 
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